pd l1  (Bio-Techne corporation)

Journal: Biomedicines

Article Title: PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

doi: 10.3390/biomedicines10081893

Figure Lengend Snippet: PD-L1 and pS6 expression in NSCLC patients’ CTCs. ( A ) CTCs stained with CK (red), PD-L1 (green) and CD45 (grey). Nuclei (blue) were stained with DAPI. ( B ) CTCs stained with CK (red), pS6 (green) and nuclei (blue). The overlay of all images is also presented. Scale bars = 10 μm.

Article Snippet: For the combination of CK/PD-L1/CD45, filters were first incubated with the goat anti-PD-L1 antibody (1:100 in 1% FBS/PBS, Novus Biologicals, Littleton, CO, USA) for 1 h at 20 °C, washed three times and incubated with an anti-goat Alexa Fluor 488 secondary antibody (1:500; Life Technologies, Carlsbad, CA, USA) for 45 min at 20 °C.

Techniques: Expressing, Staining

Journal: Biomedicines

Article Title: PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

doi: 10.3390/biomedicines10081893

Figure Lengend Snippet: Phenotypes of PD-L1 and pS6 identified in NSCLC patients and their CTCs. ( A ) Percentage of total patients with the identified phenotypes of PD-L1 ( p < 0.001 among the phenotypes at baseline) and ( B ) mean percentage of CTCs with the identified phenotypes of PD-L1 ( p < 0.001 and p = 0.003 among the phenotypes at baseline and EOT, respectively). ( C ) Percentage of total patients with the identified phenotypes of pS6 ( p = 0.021 and p = 0.033 among the phenotypes at baseline and EOT, respectively) and ( D ) mean percentage of CTCs with the identified phenotypes of pS6 ( p = 0.003 and p = 0.001 among the phenotypes at baseline and EOT, respectively). Results [in ( B , D )] are expressed as mean ± SEM. B (white bars), baseline; P 1st (purple bars), post 1st cycle; EOT (green bars), end of treatment.

Article Snippet: For the combination of CK/PD-L1/CD45, filters were first incubated with the goat anti-PD-L1 antibody (1:100 in 1% FBS/PBS, Novus Biologicals, Littleton, CO, USA) for 1 h at 20 °C, washed three times and incubated with an anti-goat Alexa Fluor 488 secondary antibody (1:500; Life Technologies, Carlsbad, CA, USA) for 45 min at 20 °C.

Techniques:

Journal: Biomedicines

Article Title: PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

doi: 10.3390/biomedicines10081893

Figure Lengend Snippet: Phenotypes of PD-L1 and pS6 identified in thirteen NSCLC patients for which samples for all time points are available. Percentage of total patients with the identified phenotypes of ( A ) PD-L1 and ( B ) pS6. B (white bars), baseline; P 1st (purple bars), post 1st cycle; EOT (green bars), end of treatment. ( C ) Kaplan–Meier analysis of 1-year OS (OS 12m ) for pS6 for the thirteen patients with samples at all time points. OS 12m according to the presence or absence of the phenotype CK low pS6 + (B, p = 0.014). B, baseline.

Article Snippet: For the combination of CK/PD-L1/CD45, filters were first incubated with the goat anti-PD-L1 antibody (1:100 in 1% FBS/PBS, Novus Biologicals, Littleton, CO, USA) for 1 h at 20 °C, washed three times and incubated with an anti-goat Alexa Fluor 488 secondary antibody (1:500; Life Technologies, Carlsbad, CA, USA) for 45 min at 20 °C.

Techniques:

Journal: Biomedicines

Article Title: PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

doi: 10.3390/biomedicines10081893

Figure Lengend Snippet: Statistically significant correlations between PD-L1 and pS6 expression among time points of evaluation.

Article Snippet: For the combination of CK/PD-L1/CD45, filters were first incubated with the goat anti-PD-L1 antibody (1:100 in 1% FBS/PBS, Novus Biologicals, Littleton, CO, USA) for 1 h at 20 °C, washed three times and incubated with an anti-goat Alexa Fluor 488 secondary antibody (1:500; Life Technologies, Carlsbad, CA, USA) for 45 min at 20 °C.

Techniques: Expressing

Journal: Biomedicines

Article Title: PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

doi: 10.3390/biomedicines10081893

Figure Lengend Snippet: Kaplan–Meier analysis of 1-year PFS (PFS 12m ) and PFS for PD-L1 and pS6. PFS 12m according to the presence or absence of the identified PD-L1 and pS6 phenotypes; ( A ) CK + PD-L1 + CD45 − (B, p = 0.073), ( B ) CK + PD-L1 + CD45 − (P 1st, p = 0.094) and ( C ) CK + pS6 + (P 1st, p = 0.003). ( D ) PFS for the presence or absence of CK low pS6 + (P 1st, p = 0.021). B, baseline; P 1st, post 1st cycle.

Article Snippet: For the combination of CK/PD-L1/CD45, filters were first incubated with the goat anti-PD-L1 antibody (1:100 in 1% FBS/PBS, Novus Biologicals, Littleton, CO, USA) for 1 h at 20 °C, washed three times and incubated with an anti-goat Alexa Fluor 488 secondary antibody (1:500; Life Technologies, Carlsbad, CA, USA) for 45 min at 20 °C.

Techniques: